Werewolf Therapeutics

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced a poster presenting preclinical data characterizing conditionally-activated IL-10 INDUKINE molecules for the treatment of colitis in animal models, a novel approach leveraging its PREDATOR™ protein engineering platform, at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy

WTX-518, a conditionally activated IL-18 INDUKINE TM molecule that resists suppression by  IL-18BP, led to complete tumor regressions in preclinical models

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to Gilead, but I wouldn't be surprised if Werewolf Therapeutics also has a competitive modified IL-12, with WTX-330. Werewolf Therapeutics is reporting data from its clinical trials of WTX-124 and WTX-330 this half (H1'24), providing near-term catalysts.

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago.

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates

–  Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024  –

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 9:20 AM ET on March 13, 2024, at the Leerink Partners Global Biopharma Conference, taking place March 11-13, 2024, in Miami, Florida.

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

-  Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINE TM programs anticipated in 2024 -

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses seen. HOWL has room to impress further, with additional data expected in H1'24. With the company testing a higher 18 mg dose, the potential for improvement on existing activity exists.

Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 8:20 AM ET on November 29 at the Evercore ISI HealthCONx Conference, taking place November 28-30, 2023, in Miami, Florida.

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

–  Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity –

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of IL-2 selectively near the tumor, minimizing toxicity. Early data from phase 1 trials showed remarkable tolerability and PK/PD, as well as the faintest signals of efficacy.

Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days

Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This clinical trial is ongoing and has the company treating patients with advanced or metastatic solid tumors with its interleukin 2 INDUKINE molecule.

Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?

WATERTOWN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company's lead clinical program, WTX-124x2101. This clinical program is an ongoing, multi-center Phase 1/1b clinical trial of WTX-124, Werewolf's interleukin 2 (IL-2) INDUKINE molecule, in patients with advanced or metastatic solid tumors. The preliminary data will be presented today at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting in San Diego, California.

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that a poster describing interim first-in-human clinical results from initial monotherapy dose-escalation cohorts in the ongoing Phase 1/1b study of WTX-124 will be presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California. Additional posters with preclinical data supporting the PREDATOR platform and INDUKINE product candidates will also be presented at the meeting.

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

WATERTOWN, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the publication of abstracts for upcoming poster presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California.

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will participate in the following upcoming investor conferences in the month of September:

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of patients with solid tumors, expected Q4 of 2023. Another INDUKINE molecule being developed in the pipeline would be WTX-330, which is being advanced in a phase 1 open-label study treating patients with metastatic solid tumors and non-Hodgkin lymphoma. Werewolf has a collaboration agreement with Jazz Pharmaceuticals for the development of JZP898, an interferon alpha INDUKINE molecule, with potential milestone payments of up to $1.26 billion.

Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.53 per share a year ago.

News for Werewolf Therapeutics Stock (HOWL)